Core Viewpoint - Haocen Medical (002622) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, Haocen Medical reported a main revenue of 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, reflecting a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring gains and losses was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 213 million yuan, a decrease of 15.72% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -966,000 yuan, down 107.53% year-on-year [2]. - The company's debt ratio stands at 71.72%, with investment income of 2.67 million yuan and financial expenses of 31.15 million yuan [2]. - The gross profit margin is reported at 47.72% [2]. Stock Performance - As of February 3, 2026, Haocen Medical's stock closed at 2.98 yuan, down 1.97% with a turnover rate of 3.55% [1]. - The trading volume was 298,500 hands, with a total transaction amount of 89.67 million yuan [1]. - On February 3, the net inflow of main funds was 4.89 million yuan, accounting for 5.45% of the total transaction amount [1]. - Retail investors experienced a net outflow of 2.66 million yuan, representing 2.97% of the total transaction amount [1].

Group 1 - The company's core business includes dental medical services and the research, production, and sales of permanent magnetic switches and high/low voltage switchgear products [5] - The company faces intensified market competition in its dental medical services, leading to increased customer acquisition costs and a significant decline in average transaction value, resulting in a notable decrease in profits compared to the previous year [5] - The company plans to recognize impairment losses on goodwill and long-term equity investments due to the cautious principle, anticipating that some investments will have recoverable amounts lower than their book values, leading to an overall loss in performance for the year 2025 [5] Group 2 - Historical total revenue and net profit growth rates are presented, indicating fluctuations in performance over the years [7] - The total revenue and net profit have shown significant year-on-year growth variations, with projections indicating a decline in 2025 [8] - The company’s financial metrics such as price-to-earnings ratio, price-to-book ratio, and price-to-sales ratio are discussed, highlighting the challenges in valuation during loss periods [12]